Twist Bioscience (TWST) announced the appointment of Adam Laponis as chief financial officer. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. Laponis joins Twist from Eargo (EAR), where he served as chief financial officer, responsible for finance, accounting, investor relations, business operations, internal audit and information technology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience named a best idea for 2024 at TD Cowen
- Twist Bioscience price target raised to $30 from $26 at Barclays
- Twist Bioscience price target raised to $32 from $26 at Evercore ISI
- Twist Bioscience sees FY24 revenue $285M-$290M, consensus $298.67M
- Twist Bioscience sees Q1 revenue $67M-$68M, consensus $63.45M
